Company news
Ensysce Biosciences, Inc. (NASDAQ:ENSC) news
Ensysce Biosciences, Inc. news releases on 6ix. Latest, Sep 15, 2026: Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing…
Press releases & updates
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
September 15, 2026
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
September 14, 2026
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
September 2, 2026
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
August 31, 2026
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
August 6, 2026
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
July 14, 2026
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
June 26, 2026
Ensysce Biosciences Reports First Quarter 2026 Financial Results
May 15, 2026
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
May 12, 2026
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
April 15, 2026
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
April 6, 2026
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
March 29, 2026
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans
March 3, 2026
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
March 3, 2026
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
March 2, 2026
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
February 24, 2026
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
February 22, 2026
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
January 28, 2026
Ensysce Biosciences Expands Global Opioid Patent Portfolio
January 21, 2026
Ensysce Biosciences Expands Global Opioid Patent Portfolio
January 20, 2026
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
January 8, 2026
Ensysce Biosciences Issues Annual Shareholder Letter
January 5, 2026
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
December 9, 2025
Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
December 2, 2025
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
November 20, 2025
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
November 19, 2025
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
November 17, 2025
Ensysce Biosciences Reports Third Quarter 2025 Financial Results
November 14, 2025
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
October 10, 2025
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
September 4, 2025
Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
August 19, 2025
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
August 13, 2025
Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
July 31, 2025
Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
July 30, 2025
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
July 16, 2025
Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
June 24, 2025
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
June 11, 2025
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
June 4, 2025
Ensysce Biosciences Reports First Quarter 2025 Financial Results
May 13, 2025
Ensysce Biosciences Bolsters Management Team with Regulatory Expert
May 12, 2025
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
April 24, 2025
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
April 23, 2025
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
April 23, 2025
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
April 22, 2025
Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
April 15, 2025
Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
April 14, 2025
Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 31, 2025
Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
March 18, 2025
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
March 10, 2025